The ABCs of ADCs

In this episode of the IGCS Education 360 Podcast entitled: The ABCs of ADCs, Dr. Brad Monk, from the Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network) and the University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital Phoenix, USA and Medical Director US Oncology Research Network - Gynecologic Program is joined by Dr. Kathleen Moore, Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics Associate Director Clinical Research, Director, Oklahoma TSET Phase I Program, Stephenson Cancer Center and Associate Professor, Section of Gynecologic Oncology At the University of Oklahoma Health Sciences Center to talk about Antibody-Drug Conjugate or ADCs. ADC’s are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. In this episode you will learn the following: • How exactly ADCs work? • What are the targets for ADCs? • The differences between ADC, MOA, and the differences between some of the ADCs – high DAR, and the controlled bystander effect • Importance of an optimal diagnostic assay (H-score vs PS2+ vs TPS) NS the importance of a correct dosing regimen • And finally payload in relation to ADC’s and current ongoing studies.